How should a patient scheduled for surgery who tests positive for reactive hepatitis B surface antigen (HBsAg) be managed pre‑operatively?

Management of HBsAg-Positive Patient Scheduled for Surgery

For a patient with reactive HBsAg scheduled for surgery, initiate antiviral prophylaxis with entecavir or tenofovir (TAF or TDF) immediately—ideally before surgery or at the latest simultaneously with the procedure—and continue for at least 6-12 months postoperatively. 1, 2, 3

Pre-Operative Assessment

Before proceeding with surgery, obtain the following baseline tests:

• HBV DNA level (quantitative PCR)
• ALT and liver function tests (AST, bilirubin, albumin, prothrombin time)
• HBeAg and anti-HBe status
• Complete blood count
• Anti-HBc antibody (if not already done)

These baseline values are critical for monitoring during and after antiviral therapy 1, 2.

Antiviral Prophylaxis Strategy

Drug Selection

Use high-barrier-to-resistance antivirals exclusively:

• Entecavir (preferred)
• Tenofovir alafenamide (TAF) (preferred)
• Tenofovir disoproxil fumarate (TDF) (preferred)

Avoid lamivudine due to high resistance rates, even though it has been historically used 1, 2. The 2020 ASCO guidelines and 2022 KASL guidelines explicitly recommend against low-barrier agents 1, 3.

Timing of Initiation

Start antiviral therapy as soon as possible before surgery or at the latest simultaneously with the surgical procedure. Starting prophylaxis 7 days before surgery has been shown to be more effective than waiting for HBV DNA levels to rise 2.

Do not delay surgery for antiviral initiation—the two can proceed concurrently 1.

Duration of Therapy

The duration depends on the type of surgery and immunosuppressive exposure:

• Standard surgery: Continue for at least 6 months after the procedure 1, 2
• If significant immunosuppression is involved (e.g., transplantation, cancer surgery with chemotherapy): Extend to at least 12 months postoperatively 1
• For organ transplantation (liver, kidney, etc.): Lifelong therapy is typically required 3

The 2019 and 2022 KASL guidelines emphasize that reactivation can occur more than 6 months after immunosuppressive procedures, necessitating extended prophylaxis 2.

Monitoring During and After Surgery

During Antiviral Therapy

• HBV DNA levels: Every 3-6 months 2
• ALT and liver function tests: Every 1-6 months 2
• HBeAg/anti-HBe: Every 3-6 months if initially HBeAg-positive 2

After Discontinuation of Antivirals

Critical monitoring period: Continue surveillance for at least 12 months after stopping prophylaxis, as late reactivation is well-documented 2.

• ALT levels: At least monthly for the first 3 months, then every 3 months 1
• HBV DNA: Every 1-3 months 1
• HBsAg: Every 3 months 1

Special Considerations

If HBV DNA is Elevated at Baseline (≥2,000 IU/mL)

If the patient has active viral replication before surgery, follow standard chronic hepatitis B treatment guidelines for determining when to discontinue antivirals, rather than using the shorter prophylactic duration 2. This may mean indefinite therapy depending on disease stage.

If Patient Has Cirrhosis

Do not discontinue antiviral therapy—patients with cirrhosis require lifelong treatment due to the risk of severe liver failure upon viral reactivation 2.

Coordination of Care

Refer to or consult with a hepatologist for:

• Patients with elevated baseline HBV DNA
• Those with cirrhosis or advanced fibrosis
• Determination of long-term antiviral therapy needs beyond the prophylactic period 1

Common Pitfalls to Avoid

1. Using lamivudine: Resistance develops even during short-term prophylaxis 2
2. Stopping antivirals too early: The 3-month mark post-surgery is particularly high-risk for reactivation 2
3. Inadequate post-prophylaxis monitoring: Reactivation can occur 6-12 months after stopping antivirals 2
4. Delaying surgery for HBV workup: Surgery should not be postponed; initiate antivirals concurrently 1
5. Failing to check baseline HBV DNA: This determines whether standard CHB treatment criteria apply rather than simple prophylaxis 2

Risk Stratification Context

While the provided guidelines focus heavily on chemotherapy and immunosuppression, all HBsAg-positive patients undergoing surgery with any degree of immunosuppressive exposure warrant prophylaxis 1, 3. The 2025 AGA guidelines classify surgical procedures with immunosuppression as moderate-to-high risk, supporting prophylaxis over monitoring alone 4.

Surgery itself, particularly major procedures, creates a physiologic stress and potential immunosuppressive state that can trigger HBV reactivation in chronic carriers 3, 5.